Zacks Research Brokers Raise Earnings Estimates for TBPH

Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Equities researchers at Zacks Research increased their Q4 2025 earnings per share (EPS) estimates for shares of Theravance Biopharma in a research note issued to investors on Monday, October 21st. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will earn $0.51 per share for the quarter, up from their prior forecast of $0.46. The consensus estimate for Theravance Biopharma's current full-year earnings is ($1.04) per share.

A number of other brokerages have also recently commented on TBPH. Leerink Partners cut shares of Theravance Biopharma from an "outperform" rating to a "market perform" rating and cut their price target for the company from $15.00 to $10.00 in a research note on Tuesday, August 6th. Leerink Partnrs cut Theravance Biopharma from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 6th. StockNews.com downgraded Theravance Biopharma from a "buy" rating to a "hold" rating in a research report on Saturday, August 10th. TD Cowen cut their price objective on Theravance Biopharma from $10.00 to $9.00 and set a "hold" rating for the company in a research report on Tuesday, August 6th. Finally, HC Wainwright reiterated a "buy" rating and set a $15.00 target price on shares of Theravance Biopharma in a research note on Monday, September 16th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $13.75.

Theravance Biopharma Trading Up 1.6 %

Shares of Theravance Biopharma stock traded up $0.14 during trading hours on Tuesday, reaching $8.80. 134,238 shares of the company's stock were exchanged, compared to its average volume of 360,218. The company has a 50 day moving average of $8.20 and a two-hundred day moving average of $8.76. The stock has a market cap of $430.50 million, a P/E ratio of -9.57 and a beta of 0.25. Theravance Biopharma has a fifty-two week low of $7.44 and a fifty-two week high of $11.71.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last announced its quarterly earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.25). The company had revenue of $14.26 million during the quarter, compared to the consensus estimate of $15.81 million. Theravance Biopharma had a negative net margin of 73.61% and a negative return on equity of 21.29%. During the same period in the previous year, the firm posted ($0.28) EPS.

Institutional Investors Weigh In On Theravance Biopharma

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Squarepoint Ops LLC acquired a new stake in shares of Theravance Biopharma in the second quarter valued at approximately $986,000. Marshall Wace LLP increased its stake in Theravance Biopharma by 83.6% during the 2nd quarter. Marshall Wace LLP now owns 297,499 shares of the biopharmaceutical company's stock worth $2,523,000 after acquiring an additional 135,426 shares during the period. Bank of Montreal Can raised its holdings in Theravance Biopharma by 141.0% in the 2nd quarter. Bank of Montreal Can now owns 160,138 shares of the biopharmaceutical company's stock valued at $1,414,000 after acquiring an additional 93,702 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Theravance Biopharma during the 2nd quarter valued at $129,000. Finally, Hsbc Holdings PLC bought a new stake in shares of Theravance Biopharma during the 2nd quarter valued at $108,000. Institutional investors and hedge funds own 99.10% of the company's stock.

Insider Buying and Selling at Theravance Biopharma

In other news, major shareholder Eli Samaha acquired 999,800 shares of Theravance Biopharma stock in a transaction dated Wednesday, August 7th. The stock was bought at an average price of $7.80 per share, for a total transaction of $7,798,440.00. Following the completion of the acquisition, the insider now directly owns 9,511,150 shares in the company, valued at approximately $74,186,970. The trade was a 0.00 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 6.90% of the company's stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.